1
|
Kimberley FC and Screaton GR: Following a
TRAIL: Update on a ligand and its five receptors. Cell Res.
14:359–372. 2004. View Article : Google Scholar : PubMed/NCBI
|
2
|
Bernard D, Quatannens B, Vandenbunder B
and Abbadie C: Rel/NF-kappaB transcription factors protect against
tumor necrosis factor (TNF)-related apoptosis-inducing ligand
(TRAIL)-induced apoptosis by up-regulating the TRAIL decoy receptor
DcR1. J Biol Chem. 276:27322–27328. 2001. View Article : Google Scholar : PubMed/NCBI
|
3
|
Wiley SR, Schooley K, Smolak PJ, Din WS,
Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA,
et al: Identification and characterization of a new member of the
TNF family that induces apoptosis. Immunity. 3:673–682. 1995.
View Article : Google Scholar : PubMed/NCBI
|
4
|
Li X, Ling V and Li PC: Same-single-cell
analysis for the study of drug efflux modulation of multidrug
resistant cells using a microfluidic chip. Anal Chem. 80:4095–4102.
2008. View Article : Google Scholar : PubMed/NCBI
|
5
|
Mundhenke C, Weigel MT, Sturner KH, Roesel
F, Meinhold-Heerlein I, Bauerschlag DO, Schem C, Hilpert F, Jonat W
and Maass N: Novel treatment of ovarian cancer cell lines with
imatinib mesylate combined with paclitaxel and carboplatin leads to
receptor-mediated antiproliferative effects. J Cancer Res Clin
Oncol. 134:1397–1405. 2008. View Article : Google Scholar : PubMed/NCBI
|
6
|
Seeber LM and van Diest PJ: Epigenetics in
ovarian cancer. Methods Mol Biol. 863:253–269. 2012. View Article : Google Scholar : PubMed/NCBI
|
7
|
Yi C, Zhang L, Li L, Liu X, Ling S, Zhang
F and Liang W: Establishment of an orthotopic transplantation tumor
model in nude mice using a drug-resistant human ovarian cancer cell
line with a high expression of c-Kit. Oncol Lett. 8:2611–2615.
2014.PubMed/NCBI
|
8
|
Belotte J, Fletcher NM, Awonuga AO, Alexis
M, Abu-Soud HM, Saed MG, Diamond MP and Saed GM: The role of
oxidative stress in the development of cisplatin resistance in
epithelial ovarian cancer. Reprod Sci. 21:503–508. 2014. View Article : Google Scholar :
|
9
|
Fatima S, Al-Mohaimeed N, Arjumand S, Banu
N, Al-Jameil N and Al-Shaikh Y: Effect of pre- and post-combined
multidoses of epigallocatechin gallate and coenzyme Q10 on
cisplatin-induced oxidative stress in rat kidney. J Biochem Mol
Toxicol. 29:91–97. 2015. View Article : Google Scholar
|
10
|
Lin L, Zheng J, Zhu W and Jia N:
Nephroprotective effect of gelsemine against cisplatin-induced
toxicity is mediated via attenuation of oxidative stress. Cell
Biochem Biophys. 71:535–541. 2015. View Article : Google Scholar
|
11
|
Huang C, Han Y, Wang Y, Sun X, Yan S, Yeh
ET, Chen Y, Cang H, Li H, Shi G, et al: SENP3 is responsible for
HIF-1 transactivation under mild oxidative stress via p300
de-SUMOylation. EMBO J. 28:2748–2762. 2009. View Article : Google Scholar : PubMed/NCBI
|
12
|
López-Lázaro M: Dual role of hydrogen
peroxide in cancer: Possible relevance to cancer chemoprevention
and therapy. Cancer Lett. 252:1–8. 2007. View Article : Google Scholar
|
13
|
Suzuki-Karasaki Y, Suzuki-Karasaki M,
Uchida M and Ochiai T: Depolarization controls TRAIL-sensitization
and tumor-selective killing of cancer cells: Crosstalk with ROS.
Front Oncol. 4:1282014. View Article : Google Scholar : PubMed/NCBI
|
14
|
Wang J and Yi J: Cancer cell killing via
ROS: To increase or decrease, that is the question. Cancer Biol
Ther. 7:1875–1884. 2008. View Article : Google Scholar : PubMed/NCBI
|
15
|
Xia C, Meng Q, Liu LZ, Rojanasakul Y, Wang
XR and Jiang BH: Reactive oxygen species regulate angiogenesis and
tumor growth through vascular endothelial growth factor. Cancer
Res. 67:10823–10830. 2007. View Article : Google Scholar : PubMed/NCBI
|
16
|
Chan DW, Liu VW, Tsao GS, Yao KM, Furukawa
T, Chan KK and Ngan HY: Loss of MKP3 mediated by oxidative stress
enhances tumorigenicity and chemoresistance of ovarian cancer
cells. Carcinogenesis. 29:1742–1750. 2008. View Article : Google Scholar : PubMed/NCBI
|
17
|
Shigetomi H, Tsunemi T, Haruta S, Kajihara
H, Yoshizawa Y, Tanase Y, Furukawa N, Yoshida S, Sado T and
Kobayashi H: Molecular mechanisms linking endometriosis under
oxidative stress with ovarian tumorigenesis and therapeutic
modalities. Cancer Invest. 30:473–480. 2012. View Article : Google Scholar : PubMed/NCBI
|
18
|
King SM, Quartuccio SM, Vanderhyden BC and
Burdette JE: Early transformative changes in normal ovarian surface
epithelium induced by oxidative stress require Akt upregulation,
DNA damage and epithelial-stromal interaction. Carcinogenesis.
34:1125–1133. 2013. View Article : Google Scholar : PubMed/NCBI
|
19
|
Martinez-Outschoorn UE, Curry JM, Ko YH,
Lin Z, Tuluc M, Cognetti D, Birbe RC, Pribitkin E, Bombonati A,
Pestell RG, et al: Oncogenes and inflammation rewire host energy
metabolism in the tumor microenvironment: RAS and NFκB target
stromal MCT4. Cell Cycle. 12:2580–2597. 2013. View Article : Google Scholar : PubMed/NCBI
|
20
|
Choi K, Ryu SW, Song S, Choi H, Kang SW
and Choi C: Caspase-dependent generation of reactive oxygen species
in human astrocytoma cells contributes to resistance to
TRAIL-mediated apoptosis. Cell Death Differ. 17:833–845. 2010.
View Article : Google Scholar
|
21
|
Yi L, Zongyuan Y, Cheng G, Lingyun Z,
Guilian Y and Wei G: Quercetin enhances apoptotic effect of tumor
necrosis factor-related apoptosis-inducing ligand (TRAIL) in
ovarian cancer cells through reactive oxygen species (ROS) mediated
CCAAT enhancer-binding protein homologous protein (CHOP)-death
receptor 5 pathway. Cancer Sci. 105:520–527. 2014. View Article : Google Scholar : PubMed/NCBI
|
22
|
Lee MW, Park SC, Kim JH, Kim IK, Han KS,
Kim KY, Lee WB, Jung YK and Kim SS: The involvement of oxidative
stress in tumor necrosis factor (TNF)-related apoptosis-inducing
ligand (TRAIL)-induced apoptosis in HeLa cells. Cancer Lett.
182:75–82. 2002. View Article : Google Scholar : PubMed/NCBI
|
23
|
Wang J, Jin L, Li X and Deng H, Chen Y,
Lian Q, Ge R and Deng H: Gossypol induces apoptosis in ovarian
cancer cells through oxidative stress. Mol Biosyst. 9:1489–1497.
2013. View Article : Google Scholar : PubMed/NCBI
|
24
|
Das A, Banik NL and Ray SK: Garlic
compounds generate reactive oxygen species leading to activation of
stress kinases and cysteine proteases for apoptosis in human
glioblastoma T98G and U87MG cells. Cancer. 110:1083–1095. 2007.
View Article : Google Scholar : PubMed/NCBI
|
25
|
Lee DH, Rhee JG and Lee YJ: Reactive
oxygen species up-regulate p53 and Puma; a possible mechanism for
apoptosis during combined treatment with TRAIL and wogonin. Br J
Pharmacol. 157:1189–1202. 2009. View Article : Google Scholar : PubMed/NCBI
|
26
|
Powolny AA and Singh SV: Multitargeted
prevention and therapy of cancer by diallyl trisulfide and related
Allium vegetable-derived organosulfur compounds. Cancer Lett.
269:305–314. 2008. View Article : Google Scholar : PubMed/NCBI
|
27
|
Shenoy K, Wu Y and Pervaiz S: LY303511
enhances TRAIL sensitivity of SHEP-1 neuroblastoma cells via
hydrogen peroxide-mediated mitogen-activated protein kinase
activation and up-regulation of death receptors. Cancer Res.
69:1941–1950. 2009. View Article : Google Scholar : PubMed/NCBI
|
28
|
Pasini A and Zunino F: New cisplatin
analogues - on the way to better antitumor agents. Angew Chem Int
Ed Engl. 26:615–624. 1987. View Article : Google Scholar
|
29
|
Poirier MC, Lippard SJ, Zwelling LA, Ushay
HM, Kerrigan D, Thill CC, Santella RM, Grunberger D and Yuspa SH:
Antibodies elicited against
cis-diamminedichloroplatinum(II)-modified DNA are specific for
cis-diamminedichloroplatinum(II)-DNA adducts formed in vivo and in
vitro. Proc Natl Acad Sci USA. 79:6443–6447. 1982. View Article : Google Scholar : PubMed/NCBI
|
30
|
Wong E and Giandomenico CM: Current status
of platinum-based antitumor drugs. Chem Rev. 99:2451–2466. 1999.
View Article : Google Scholar
|
31
|
Calderone V, Casini A, Mangani S, Messori
L and Orioli PL: Structural investigation of cisplatin-protein
interactions: Selective platination of His19 in a cuprozinc
superoxide dismutase. Angew Chem Int Ed Engl. 45:1267–1269. 2006.
View Article : Google Scholar : PubMed/NCBI
|
32
|
DeConti RC, Toftness BR, Lange RC and
Creasey WA: Clinical and pharmacological studies with
cis-diamminedichloroplatinum (II). Cancer Res. 33:1310–1315.
1973.PubMed/NCBI
|
33
|
Hagendoorn J, Tong R, Fukumura D, Lin Q,
Lobo J, Padera TP, Xu L, Kucherlapati R and Jain RK: Onset of
abnormal blood and lymphatic vessel function and interstitial
hypertension in early stages of carcinogenesis. Cancer Res.
66:3360–3364. 2006. View Article : Google Scholar : PubMed/NCBI
|
34
|
Jain RK: Normalizing tumor vasculature
with anti-angiogenic therapy: A new paradigm for combination
therapy. Nat Med. 7:987–989. 2001. View Article : Google Scholar : PubMed/NCBI
|
35
|
Behrens BC, Hamilton TC, Masuda H,
Grotzinger KR, Whang-Peng J, Louie KG, Knutsen T, McKoy WM, Young
RC and Ozols RF: Characterization of a
cis-diammine-dichloroplatinum(II)-resistant human ovarian cancer
cell line and its use in evaluation of platinum analogues. Cancer
Res. 47:414–418. 1987.PubMed/NCBI
|
36
|
Bertsch U, Röder C, Kalthoff H and
Trauzold A: Compartmentalization of TNF-related apoptosis-inducing
ligand (TRAIL) death receptor functions: Emerging role of nuclear
TRAIL-R2. Cell Death Dis. 5:e13902014. View Article : Google Scholar : PubMed/NCBI
|
37
|
Ashraf NU and Sheikh TA: Endoplasmic
reticulum stress and oxidative stress in the pathogenesis of
non-alcoholic fatty liver disease. Free Radic Res. 49:1405–1418.
2015. View Article : Google Scholar : PubMed/NCBI
|
38
|
Afanas'ev I: Reactive oxygen species
signaling in cancer: Comparison with aging. Aging Dis. 2:219–230.
2011.
|